New oral combination chemotherapy for colorectal cancer

Lonsurf (trifluridine/tipiracil) is a new oral therapy for the treatment of metastatic colorectal cancer which allows patients to avoid long periods of IV treatment.

Lonsurf is taken orally within an hour after the morning and evening meals. | SCIENCE PHOTO LIBRARY
Lonsurf is taken orally within an hour after the morning and evening meals. | SCIENCE PHOTO LIBRARY

Lonsurf combines trifluridine, an antineoplastic thymidine-based nucleoside analogue, with tipiracil hydrochloride, a thymidine phosphorylase inhibitor, in either 15mg/6.14 mg or 20mg/8.19mg tablets.

Trifluridine is incorporated into cellular DNA via phosphorylation, thereby disrupting DNA function and cellular proliferation. Tipiracil hydrochloride prevents the normal degradation of trifluridine by thymidine phosphorylase.

Further information
View Lonsurf drug record
Summary of Product Characteristics
Manufacturer: Servier Laboratories
MIMS Cancer Clinic

Lonsurf is indicated in patients who have been previously treated with, or who are not considered candidates for, available treatments (including fluoropyrimidine-, oxiplatin- or irinotecan-based chemotherapies, anti-VEGF agents and anti-EGFR agents).

Evidence base

LonsurfFindings of the RECOURSE study (n=800) showed trifluridine/tipiracil to be superior to placebo in treating patients with metastatic colorectal cancer who were refractory to or unable to tolerate standard chemotherapies. Participants were randomised to receive either trifluridine/tipiracil (n=534) or placebo (n=266), both with best supportive care.

Median overall survival, the primary endpoint, was 7.1 months (95% CI 6.5-7.8) in the trifluridine/tipiracil group compared with 5.3 months (95% CI 4.6-6.0) in the placebo group (p<0.0001). One-year survival rates were also higher with trifluridine/tipiracil than placebo (26.6% vs 17.6%).

The most common adverse effects of trifluridine/tipiracil that resulted in treatment discontinuation or dose reduction, interruption or delay included neutropenia, anaemia, fatigue, diarrhoea and dyspnoea.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases